NCT00851253 · OUTCOME

Rates of Adverse Events Associated With Treatment

Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer · Source last updated 2018-01-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 1 year

What was measured

Number of patients with serious adverse events possibly related, probably related or definitely related to the study treatment

Analysis population: One subject in the Boost Arm was withdrawn prior to Cyberknife therapy due to disease progression and was therefore not analyzed.

Groups in this outcome

Group 1 (CK SRS Boost Therapy)

Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy. stereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses

Group 2 (CK SRS Salvage Therapy)

Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly. stereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Group 1 (CK SRS Boost Therapy)	1
Group 2 (CK SRS Salvage Therapy)	10

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Group 1 (CK SRS Boost Therapy)	1	Not reported	Not reported	Not reported	Not reported
Group 2 (CK SRS Salvage Therapy)	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0

denoms

counts
group Id
OG000
value
1
group Id
OG001
value
10
units
Participants

description

Number of patients with serious adverse events possibly related, probably related or definitely related to the study treatment

groups

description
Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy. stereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses
id
OG000
title
Group 1 (CK SRS Boost Therapy)
description
Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly. stereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses
id
OG001
title
Group 2 (CK SRS Salvage Therapy)

param Type

COUNT_OF_PARTICIPANTS

population Description

One subject in the Boost Arm was withdrawn prior to Cyberknife therapy due to disease progression and was therefore not analyzed.

reporting Status

POSTED

time Frame

1 year

title

Rates of Adverse Events Associated With Treatment

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice